The AXL Receptor is a Sensor of Ligand Spatial Heterogeneity
Aaron S Meyer1, Annelien J M Zweemer1, Douglas A Lauffenburger1
1Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge MA 02139 ; Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge MA 02139.
Abstract:
The AXL receptor is a TAM (Tyro3, AXL, MerTK) receptor tyrosine kinase (RTK) important in physiological inflammatory processes such as blood clotting, viral infection, and innate immune-mediated cell clearance. Overexpression of the receptor in a number of solid tumors is increasingly appreciated as a key drug resistance and tumor dissemination mechanism. Although the ligand-receptor (Gas6-AXL) complex structure is known, literature reports on ligand-mediated signaling have provided conflicting conclusions regarding the influence of other factors such as phosphatidylserine binding, and a detailed, mechanistic picture of AXL activation has not emerged. Integrating quantitative experiments with mathematical modeling, we show here that AXL operates to sense local spatial heterogeneity in ligand concentration, a feature consistent with its physiological role in inflammatory cell responses. This effect arises as a result of an intricate reaction-diffusion interaction. Our results demonstrate that AXL functions distinctly from other RTK families, a vital insight for envisioned design of AXL-targeted therapeutic intervention.
Insights
The AXL receptor tyrosine kinase (RTK) plays a role in inflammation and cancer. This study reveals AXL senses ligand concentration through reaction-diffusion, offering new therapeutic targets.
Area of Science:
- Biochemistry
- Cell Biology
- Systems Biology
Background:
- AXL receptor tyrosine kinase (RTK) is implicated in inflammation and cancer progression.
- AXL overexpression contributes to drug resistance and tumor dissemination in solid tumors.
- Existing knowledge on Gas6-AXL signaling lacks mechanistic detail regarding activation.
Purpose of the Study:
- To elucidate the detailed, mechanistic picture of AXL activation.
- To understand how ligand-receptor interactions influence AXL signaling.
- To provide insights for designing targeted AXL therapeutics.
Main Methods:
- Integration of quantitative experimental data.
- Application of mathematical modeling approaches.
- Analysis of reaction-diffusion interactions.
Main Results:
- AXL functions by sensing local spatial heterogeneity in ligand concentration.
- This sensing mechanism is driven by complex reaction-diffusion interactions.
- AXL activation mechanism differs from other receptor tyrosine kinase families.
Conclusions:
- AXL's distinct activation mechanism is crucial for its physiological roles in inflammation.
- Understanding AXL's unique signaling provides a vital insight for developing targeted therapies.
- This research paves the way for novel AXL-targeted therapeutic interventions.
More Related Videos
12:30Avidity-based Extracellular Interaction Screening AVEXIS for the Scalable Detection of Low-affinity Extracellular Receptor-Ligand Interactions
Published on: March 5, 2012
07:41A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
Published on: February 20, 2018
Related Concept Videos
The Two-State Receptor Model
The binding affinity of a drug determines its interaction with...
Signal Transduction: Overview
Typically, signal transduction involves three...
Ligand-Gated Ion Channel Receptor: Gating Mechanism
Ligand Binding Sites
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
Spare Receptors
Drug-Receptor Interactions
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
